Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Enviomycin [INN]
RN: 33103-22-9
UNII: XU299C23A2
InChIKey: HPWIIERXAFODPP-GHBBWTPBSA-N

Note

  • Cyclic basic peptide related to VIOMYCIN. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

Molecular Formula

  • C25-H43-N13-O10

Molecular Weight

  • 685.6957
 

Classification Codes

  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antibiotics, Antitubercular
  • Antitubercular Agents
  • Drug / Therapeutic Agent
  • Natural Product
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Enviomycin
  • Enviomycin [INN]

MeSH Heading

  • Enviomycin

Synonyms

  • Enviomycin
  • Enviomycina
  • Enviomycina [INN-Spanish]
  • Enviomycine
  • Enviomycine [INN-French]
  • Enviomycinum
  • Enviomycinum [INN-Latin]
  • tereoisomer of ((15-(3,6-diamino-4-hydroxyhexanamido)-3-(hexahydro-2-imino-4-pyrimidinyl)-9,12-bis(hydroxymethyl-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclohexadec-6-ylidene)methyl)urea
  • Tuberactinomycin N
  • Tuberactinomycin N; stereoisomer of ((15-(3,6-diamino-4-hydroxyhexanamido)-3-(hexahydro-2-imino-4-pyrimidinyl)-9,12-bis(hydroxymethyl-2,5,8,11,14-pentaoxo-1,4,7,10,13-pentaazacyclohexadec-6-ylidene)methyl)urea
  • UNII-XU299C23A2

Systematic Names

  • Tuberactinomycin N
  • Viomycin, 1-((3R,4R)-4-hydroxy-3,6-diaminohexanoic acid)-6-(L-2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycine)-, (R)-
  • Viomycin, 1-(threo-4-hydroxy-L-3,6-diaminohexanoic acid)-6-(L-2-(2-amino-1,4,5,6-tetrahydro-4-pyrimidinyl)glycine)-, (R)-

Registry Numbers

CAS Registry Number

  • 33103-22-9

FDA UNII

  • XU299C23A2

Other Registry Number

  • 33987-25-6

System Generated Number

  • 0033103229

Structure Descriptors

InChI

1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1

InChIKey

HPWIIERXAFODPP-GHBBWTPBSA-N

Smiles

C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C\NC(=O)N)/C(=O)N2)CO)CO)NC(=O)C[C@H]([C@@H](CCN)O)N)N

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intramuscular > 3gm/kg (3000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 530, 1975.
mouse LD50 intravenous 370mg/kg (370mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 530, 1975.
mouse LD50 oral > 3gm/kg (3000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 530, 1975.
rat LD50 intramuscular > 2gm/kg (2000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 530, 1975.
rat LD50 intravenous 640mg/kg (640mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 530, 1975.
rat LD50 oral > 3gm/kg (3000mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 6, Pg. 530, 1975.